

# Gary Maartens

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/8655722/publications.pdf](https://exaly.com/author-pdf/8655722/publications.pdf)

Version: 2024-02-01

301  
papers

16,546  
citations

17319

63  
h-index

22041

114  
g-index

372  
all docs

372  
docs citations

372  
times ranked

16776  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. <i>Lancet Infectious Diseases</i> , The, 2008, 8, 516-523.	8.9	696
2	HIV infection: epidemiology, pathogenesis, treatment, and prevention. <i>Lancet</i> , The, 2014, 384, 258-271.	12.1	635
3	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 291-360.	10.4	478
4	Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. <i>Aids</i> , 2004, 18, 887-895.	2.2	476
5	Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. <i>Clinical Infectious Diseases</i> , 2021, 73, e2005-e2015.	5.7	440
6	Antiretroviral Therapy Adherence, Virologic and Immunologic Outcomes in Adolescents Compared With Adults in Southern Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 65-71.	2.2	370
7	Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. <i>Aids</i> , 2010, 24, 2381-2390.	2.2	335
8	Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies. <i>PLoS Medicine</i> , 2011, 8, e1000391.	8.4	331
9	Adherence to Nonnucleoside Reverse Transcriptase Inhibitor-Based HIV Therapy and Virologic Outcomes. <i>Annals of Internal Medicine</i> , 2007, 146, 564.	10.2	324
10	Miliary tuberculosis: Rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults. <i>American Journal of Medicine</i> , 1990, 89, 291-296.	1.4	261
11	Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. <i>Aids</i> , 2010, 24, 563-572.	2.2	237
12	Adherence to Highly Active Antiretroviral Therapy Assessed by Pharmacy Claims Predicts Survival in HIV-Infected South African Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, 78-84.	2.2	233
13	Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2014, 384, 682-690.	12.1	233
14	Severe Hepatotoxicity Associated with Nevirapine Use in HIV-Infected Subjects. <i>Journal of Infectious Diseases</i> , 2005, 191, 825-829.	3.9	228
15	Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 699-706.	10.4	198
16	Effect of HIV-1 Infection on T-Cell-based and Skin Test Detection of Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 514-520.	6.6	196
17	Complications of Antiretroviral Therapy in Patients with Tuberculosis: Drug Interactions, Toxicity, and Immune Reconstitution Inflammatory Syndrome. <i>Journal of Infectious Diseases</i> , 2007, 196, S63-S75.	3.9	191
18	Outcomes of Nevirapine- and Efavirenz-Based Antiretroviral Therapy When Coadministered With Rifampicin-Based Antitubercular Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 530.	7.0	170

#	ARTICLE	IF	CITATIONS
19	Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2020, 7, e666-e676.	4.6	165
20	Neurologic Manifestations of Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome: A Case Series. <i>Clinical Infectious Diseases</i> , 2009, 48, e96-e107.	5.7	163
21	CD4 Decline and Incidence of Opportunistic Infections in Cape Town, South Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 42, 464-469.	2.2	160
22	Treatment Supporter to Improve Adherence to Antiretroviral Therapy in HIV-Infected South African Adults. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 43, S127-S133.	2.2	158
23	Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. <i>New England Journal of Medicine</i> , 2018, 379, 1915-1925.	30.1	149
24	Pharmacy Refill Adherence Compared with CD4 Count Changes for Monitoring HIV-Infected Adults on Antiretroviral Therapy. <i>PLoS Medicine</i> , 2008, 5, e109.	8.4	146
25	Type 1 Helper T Cells and FoxP3-positive T Cells in HIV-Associated Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 1083-1089.	6.6	141
26	The <i>SLCO1B1</i> rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4122-4127.	3.4	134
27	Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 979-985.	1.2	134
28	Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. <i>European Respiratory Journal</i> , 2011, 37, 1248-1259.	7.5	132
29	Risk Factors for Developing Tuberculosis in HIV-Infected Adults From Communities With a Low or Very High Incidence of Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 23, 75-80.	2.2	129
30	Substitutions Due to Antiretroviral Toxicity or Contraindication in the First 3 years of Antiretroviral Therapy in a Large South African Cohort. <i>Antiviral Therapy</i> , 2007, 12, 753-760.	1.0	118
31	Selective Increase in Plasma Tumor Necrosis Factor- $\alpha$ and Concomitant Clinical Deterioration after Initiating Therapy in Patients with Severe Tuberculosis. <i>Journal of Infectious Diseases</i> , 1998, 178, 580-584.	3.9	117
32	Effect of Rifampicin on Lopinavir Pharmacokinetics in HIV-Infected Children With Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 47, 566-569.	2.2	114
33	Cost-Effectiveness of Highly Active Antiretroviral Therapy in South Africa. <i>PLoS Medicine</i> , 2005, 3, e4.	8.4	111
34	Concurrent infections and HIV pathogenesis. <i>Aids</i> , 2000, 14, 2071-2081.	2.2	110
35	Clinical characteristics and initial management of patients with tuberculous pericarditis in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI Africa) registry. <i>BMC Infectious Diseases</i> , 2006, 6, 2.	3.0	104
36	Low Lopinavir Plasma or Hair Concentrations Explain Second-Line Protease Inhibitor Failures in a Resource-Limited Setting. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 333-339.	2.2	101

#	ARTICLE	IF	CITATIONS
37	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 820-826.	10.4	97
38	High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. <i>European Respiratory Journal</i> , 2018, 52, 1801528.	7.5	96
39	Novel Relationship between Tuberculosis Immune Reconstitution Inflammatory Syndrome and Antitubercular Drug Resistance. <i>Clinical Infectious Diseases</i> , 2009, 48, 667-676.	5.7	94
40	A Randomized Controlled Trial of Real-Time Electronic Adherence Monitoring With Text Message Dosing Reminders in People Starting First-Line Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 70, 495-502.	2.2	93
41	Impact of enhanced tuberculosis diagnosis in South Africa: A mathematical model of expanded culture and drug susceptibility testing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 11293-11298.	7.6	88
42	Neuronal toxicity of efavirenz: a systematic review. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 841-846.	2.5	88
43	Tuberculous pleural effusions: increased culture yield with bedside inoculation of pleural fluid and poor diagnostic value of adenosine deaminase.. <i>Thorax</i> , 1991, 46, 96-99.	7.2	84
44	Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. <i>Aids</i> , 2010, 24, 1273-1280.	2.2	84
45	High Prevalence of Subtherapeutic Plasma Concentrations of Efavirenz in Children. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 45, 133-136.	2.2	83
46	HIV-associated tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling. <i>Nature Communications</i> , 2015, 6, 8451.	13.2	83
47	When to Initiate Highly Active Antiretroviral Therapy in Sub-Saharan Africa? A South African Cost-Effectiveness Study. <i>Antiviral Therapy</i> , 2006, 11, 63-72.	1.0	82
48	CD4 and total lymphocyte counts as predictors of HIV disease progression. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1996, 89, 505-508.	0.5	81
49	Southern African guidelines on the safe use of pre-exposure prophylaxis in persons at risk of acquiring HIV-1 infection. <i>Southern African Journal of HIV Medicine</i> , 2016, 17, 455.	0.9	80
50	A comparative study of the polymerase chain reaction and conventional procedures for the diagnosis of tuberculous pleural effusion. <i>Tubercle and Lung Disease</i> , 1992, 73, 262-267.	2.0	79
51	Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. <i>Aids</i> , 2001, 15, 1143-1148.	2.2	79
52	Clinical, Immunological, and Epidemiological Importance of Antituberculosis T Cell Responses in HIV-Infected Africans. <i>Clinical Infectious Diseases</i> , 2007, 44, 1639-1646.	5.7	79
53	Factors Influencing Retention in Care after Starting Antiretroviral Therapy in a Rural South African Programme. <i>PLoS ONE</i> , 2011, 6, e19201.	2.5	76
54	CheXaid: deep learning assistance for physician diagnosis of tuberculosis using chest x-rays in patients with HIV. <i>Npj Digital Medicine</i> , 2020, 3, 115.	11.3	76

#	ARTICLE	IF	CITATIONS
55	Effect of Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy on Dysglycemia and Insulin Sensitivity in South African HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 57, 284-289.	2.2	75
56	Corticosteroid-modulated Immune Activation in the Tuberculosis Immune Reconstitution Inflammatory Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 369-377.	6.6	75
57	Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: A cross-sectional study. <i>BMC Infectious Diseases</i> , 2008, 8, 72.	3.0	74
58	Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 389-393.	3.2	72
59	Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. <i>Antiviral Therapy</i> , 2009, 14, 687-695.	1.0	72
60	Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 901-915.	4.5	69
61	Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. <i>Aids</i> , 2008, 22, 2117-2125.	2.2	67
62	Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant <i>Acinetobacter baumannii</i> infections. <i>BMC Infectious Diseases</i> , 2009, 9, 26.	3.0	66
63	QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 975-983.	8.9	66
64	South African guideline for the management of community-acquired pneumonia in adults. <i>Journal of Thoracic Disease</i> , 2017, 9, 1469-1502.	1.4	64
65	Performance of Serum C-Reactive Protein as a Screening Test for Smear-Negative Tuberculosis in an Ambulatory High HIV Prevalence Population. <i>PLoS ONE</i> , 2011, 6, e15248.	2.5	64
66	Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-Infected Children With Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 50, 439-443.	2.2	63
67	Central Nervous System Penetration of Antiretroviral Drugs: Pharmacokinetic, Pharmacodynamic and Pharmacogenomic Considerations. <i>Clinical Pharmacokinetics</i> , 2015, 54, 581-598.	3.6	63
68	Adverse Drug Reactions Causing Admission to Medical Wards. <i>Medicine (United States)</i> , 2016, 95, e3437.	1.1	62
69	<i>CYP2B6</i> Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. <i>Clinical Infectious Diseases</i> , 2021, 73, e3902-e3909.	5.7	62
70	Dissection of Regenerating T-Cell Responses against Tuberculosis in HIV-infected Adults Sensitized by <i>Mycobacterium tuberculosis</i>. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 674-683.	6.6	60
71	Association of Antiretroviral Therapy Adherence and Health Care Costs. <i>Annals of Internal Medicine</i> , 2010, 152, 18.	10.2	60
72	Interaction between Artemether-Lumefantrine and Nevirapine-Based Antiretroviral Therapy in HIV-1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5616-5623.	3.4	58

#	ARTICLE	IF	CITATIONS
73	Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 496-506.	8.9	58
74	The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2011, 93, 93-100.	4.6	57
75	Thalidomide-induced Antigen-specific Immune Stimulation in Patients with Human Immunodeficiency Virus Type 1 and Tuberculosis. <i>Journal of Infectious Diseases</i> , 2000, 181, 954-965.	3.9	56
76	Baseline Predictors of Sputum Culture Conversion in Pulmonary Tuberculosis: Importance of Cavities, Smoking, Time to Detection and W-Beijing Genotype. <i>PLoS ONE</i> , 2012, 7, e29588.	2.5	56
77	Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?. <i>AIDS Research and Therapy</i> , 2017, 14, 20.	1.8	56
78	Lopinavir Exposure is Insufficient in Children Given Double Doses of Lopinavir/Ritonavir during Rifampicin-Based Treatment for Tuberculosis. <i>Antiviral Therapy</i> , 2011, 16, 417-421.	1.0	54
79	Clinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: A prospective cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002840.	8.4	54
80	Effect of Antiretroviral Therapy on the Diagnostic Accuracy of Symptom Screening for Intensified Tuberculosis Case Finding in a South African HIV Clinic. <i>Clinical Infectious Diseases</i> , 2012, 55, 1698-1706.	5.7	51
81	Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1037-1040.	3.2	51
82	Pharmacokinetics of Lopinavir in HIV-Infected Adults Receiving Rifampin with Adjusted Doses of Lopinavir-Ritonavir Tablets. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3195-3200.	3.4	50
83	Matrix metalloproteinases and tissue damage in HIV-tuberculosis immune reconstitution inflammatory syndrome. <i>European Journal of Immunology</i> , 2014, 44, 127-136.	3.3	50
84	An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1214-1227.	6.6	50
85	Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. <i>Aids</i> , 2013, 27, 1933-1940.	2.2	48
86	Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy. <i>Medicine (United States)</i> , 2016, 95, e2844.	1.1	48
87	Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1670-1678.	3.2	48
88	Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole. <i>BMC Infectious Diseases</i> , 2006, 6, 118.	3.0	47
89	Effectiveness and Safety of Antiretrovirals with Rifampicin: Crucial Issues for High-Burden Countries. <i>Antiviral Therapy</i> , 2009, 14, 1039-1043.	1.0	47
90	Management of active tuberculosis in adults with HIV. <i>Lancet HIV</i> , the, 2019, 6, e463-e474.	4.6	47

#	ARTICLE	IF	CITATIONS
91	Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis. <i>PLoS Medicine</i> , 2009, 6, e1000189.	8.4	45
92	Is it safe to switch between efavirenz and nevirapine in the event of toxicity?. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 733-738.	8.9	43
93	Diagnostic accuracy and clinical role of rapid C-reactive protein testing in HIV-infected individuals with presumed tuberculosis in South Africa. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 20-26.	1.2	42
94	Second-Line Antiretroviral Therapy in Sub-Saharan Africa: It Is Time to Mind the Gaps. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 1181-1184.	1.2	42
95	Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 507-518.	8.9	41
96	Changes in blood pressure, glucose levels, insulin secretion and anthropometry after long term exposure to antiretroviral therapy in South African women. <i>AIDS Research and Therapy</i> , 2015, 12, 24.	1.8	40
97	Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 202-206.	3.3	39
98	Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 73-78.	2.2	39
99	<i>Mycobacterium tuberculosis</i> bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 742-752.	8.9	39
100	Patient-Nominated, Community-Based HIV Treatment Supporters: Patient Perspectives, Feasibility, Challenges, and Factors for Success in HIV-Infected South African Adults. <i>AIDS Patient Care and STDs</i> , 2013, 27, 96-102.	2.7	38
101	Anti-Retroviral Therapy Increases the Prevalence of Dyslipidemia in South African HIV-Infected Patients. <i>PLoS ONE</i> , 2016, 11, e0151911.	2.5	38
102	Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 212-217.	3.3	38
103	Risk Factors for Developing Tuberculosis in HIV-Infected Adults From Communities With a Low or Very High Incidence of Tuberculosis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 23, 75-80.	2.2	37
104	Plasma vitamin A and zinc levels in HIV-infected adults in Cape Town, South Africa. <i>British Journal of Nutrition</i> , 2003, 89, 475-482.	2.7	37
105	Increased risk of dysglycaemia in South Africans with HIV; especially those on protease inhibitors. <i>Diabetes Research and Clinical Practice</i> , 2016, 119, 41-47.	2.8	37
106	Clofazimine pharmacokinetics in patients with TB: dosing implications. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3269-3277.	3.2	37
107	Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update. <i>Southern African Journal of HIV Medicine</i> , 2020, 21, 1115.	0.9	37
108	Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans. <i>PLoS ONE</i> , 2015, 10, e0144286.	2.5	36

#	ARTICLE	IF	CITATIONS
109	Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. <i>Lancet HIV</i> , 2021, 8, e8-e15.	4.6	36
110	A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 789-795.	3.4	35
111	Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen. <i>Aids</i> , 2021, 35, 1423-1432.	2.2	35
112	Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. <i>Lancet Infectious Diseases</i> , 2022, 22, 1042-1051.	8.9	35
113	Evaluation of the World Health Organization algorithm for the diagnosis of HIV-associated sputum smear-negative tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 919-924.	1.2	34
114	Changes in estimated glomerular filtration rate over time in South African HIV-infected patients receiving tenofovir: a retrospective cohort study. <i>Journal of the International AIDS Society</i> , 2017, 20, 21317.	3.1	34
115	HIV Infection Is Associated with a Lower Incidence of Constriction in Presumed Tuberculous Pericarditis: A Prospective Observational Study. <i>PLoS ONE</i> , 2008, 3, e2253.	2.5	34
116	Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa. <i>South African Medical Journal</i> , 2012, 102, 506.	0.8	33
117	Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2377-2384.	3.2	33
118	Cytotoxic Mediators in Paradoxical HIV-Tuberculosis Immune Reconstitution Inflammatory Syndrome. <i>Journal of Immunology</i> , 2015, 194, 1748-1754.	0.8	32
119	Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations. <i>Medicine (United States)</i> , 2016, 95, e2385.	1.1	32
120	A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 311-318.	2.2	32
121	Clinical Access Program for Bedaquiline for the treatment of drug-resistant tuberculosis. <i>South African Medical Journal</i> , 2014, 104, 164.	0.8	31
122	Role of the Interleukin 10 Family of Cytokines in Patients With Immune Reconstitution Inflammatory Syndrome Associated With HIV Infection and Tuberculosis. <i>Journal of Infectious Diseases</i> , 2013, 207, 1148-1156.	3.9	30
123	Independent predictors of tuberculosis mortality in a high HIV prevalence setting: a retrospective cohort study. <i>AIDS Research and Therapy</i> , 2015, 12, 35.	1.8	30
124	The Safety, Effectiveness and Concentrations of Adjusted Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based Antitubercular Therapy. <i>PLoS ONE</i> , 2012, 7, e32173.	2.5	29
125	Effect of Different Antiretroviral Drug Regimens on Body Fat Distribution of HIV-Infected South African Women. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 557-563.	1.2	29
126	Interrater agreement of two adverse drug reaction causality assessment methods: A randomised comparison of the Liverpool Adverse Drug Reaction Causality Assessment Tool and the World Health Organization-Uppsala Monitoring Centre system. <i>PLoS ONE</i> , 2017, 12, e0172830.	2.5	29



#	ARTICLE	IF	CITATIONS
127	Third-line antiretroviral therapy in Africa: effectiveness in a Southern African retrospective cohort study. <i>AIDS Research and Therapy</i> , 2015, 12, 39.	1.8	28
128	Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 355-358.	4.0	27
129	Discovery of False Elite Controllers: HIV Antibody-Positive RNA-Negative Blood Donors Found To Be on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2019, 220, 643-647.	3.9	27
130	Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 2083-2092.	5.7	27
131	Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors. <i>BMC Infectious Diseases</i> , 2010, 10, 83.	3.0	26
132	Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms. <i>European Respiratory Journal</i> , 2012, 39, 163-171.	7.5	26
133	Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1493-1503.	3.2	26
134	A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 875-882.	2.5	26
135	Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases. <i>BMC Infectious Diseases</i> , 2019, 19, 544.	3.0	26
136	Co-trimoxazole in HIV-1 infection. <i>Lancet</i> , The, 1999, 354, 334-335.	12.1	25
137	Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study. <i>BMC Infectious Diseases</i> , 2014, 14, 664.	3.0	25
138	Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 466-472.	3.3	25
139	C-reactive protein and procalcitonin to discriminate between tuberculosis, <i>Pneumocystis jirovecii</i> pneumonia, and bacterial pneumonia in HIV-infected inpatients meeting WHO criteria for seriously ill: a prospective cohort study. <i>BMC Infectious Diseases</i> , 2018, 18, 399.	3.0	25
140	Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. <i>International Journal of Infectious Diseases</i> , 2021, 105, 688-694.	3.3	25
141	Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0014021.	3.4	25
142	Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals. <i>The Cochrane Library</i> , 2019, 2019, CD012777.	2.8	25
143	The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients. <i>BMC Infectious Diseases</i> , 2015, 16, 30.	3.0	24
144	Incremental yield and cost of urine Determine TB-LAM and sputum induction in seriously ill adults with HIV. <i>International Journal of Infectious Diseases</i> , 2018, 75, 67-73.	3.3	24

#	ARTICLE	IF	CITATIONS
145	Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 1017-1023.	1.9	23
146	Moderate to severe HIV-associated neurocognitive impairment. <i>Medicine (United States)</i> , 2016, 95, e5401.	1.1	23
147	Diagnostic accuracy of the Xpert MTB/Rif Ultra for tuberculosis adenitis. <i>BMC Infectious Diseases</i> , 2020, 20, 33.	3.0	23
148	Safety and Effectiveness of Isoniazid Preventive Therapy in Pregnant Women Living with Human Immunodeficiency Virus on Antiretroviral Therapy: An Observational Study Using Linked Population Data. <i>Clinical Infectious Diseases</i> , 2020, 71, e351-e358.	5.7	23
149	Opportunistic infections associated with HIV infection in Africa. <i>Oral Diseases</i> , 2002, 8, 76-79.	3.2	22
150	Optimizing Tuberculosis Diagnosis in Human Immunodeficiency Virus-Infected Inpatients Meeting the Criteria of Seriously Ill in the World Health Organization Algorithm. <i>Clinical Infectious Diseases</i> , 2018, 66, 1419-1426.	5.7	22
151	Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 564-571.	6.6	22
152	A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury. <i>Clinical Infectious Diseases</i> , 2021, 73, e3377-e3383.	5.7	22
153	Vertical HIV transmission in South Africa: translating research into policy and practice. <i>Lancet, The</i> , 2002, 359, 992-993.	12.1	21
154	Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 577-579.	2.2	21
155	Evaluation of Tuberculosis Treatment Response With Serial C-Reactive Protein Measurements. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy253.	0.9	21
156	Cytolytic T-cell Activity Against Mycobacterial Antigens in HIV. <i>Aids</i> , 1992, 6, 407-412.	2.2	20
157	Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts - time to implement in South Africa?. <i>South African Medical Journal</i> , 2011, 101, 232.	0.8	20
158	Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 915-919.	1.2	20
159	Mortality in Severe Human Immunodeficiency Virus-Tuberculosis Associates With Innate Immune Activation and Dysfunction of Monocytes. <i>Clinical Infectious Diseases</i> , 2017, 65, 73-82.	5.7	20
160	The Next Generation Scientist program: capacity-building for future scientific leaders in low- and middle-income countries. <i>BMC Medical Education</i> , 2018, 18, 233.	2.5	20
161	Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis. <i>Lancet HIV</i> , 2022, 9, e233-e241.	4.6	20
162	Hemostatic changes associate with mortality in hospitalized patients with HIV-associated tuberculosis: a prospective cohort study. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw532.	3.9	19

#	ARTICLE	IF	CITATIONS
163	Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.4	19
164	Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1146-1154.	3.2	19
165	Tuberculosis preventive therapy: An underutilised strategy to reduce individual risk of TB and contribute to TB control. <i>South African Medical Journal</i> , 2014, 104, 339.	0.8	18
166	Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1313-1319.	1.9	18
167	The determinants and impact of diagnostic delay in lymphoma in a TB and HIV endemic setting. <i>BMC Cancer</i> , 2019, 19, 384.	2.6	18
168	Increased Mortality With Delayed and Missed Switch to Second-Line Antiretroviral Therapy in South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 107-113.	2.2	18
169	Impact of immune reconstitution inflammatory syndrome on antiretroviral therapy adherence. <i>Patient Preference and Adherence</i> , 2012, 6, 887.	1.9	17
170	Mitochondrial Genomics and Antiretroviral Therapy-Associated Metabolic Complications in HIV-Infected Black South Africans: A Pilot Study. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1031-1039.	1.2	17
171	Complications of Antiretroviral Therapy Initiation in Hospitalised Patients with HIV-Associated Tuberculosis. <i>PLoS ONE</i> , 2013, 8, e54145.	2.5	17
172	Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , 2016, 30, 1279-1286.	2.2	17
173	The Cape Town Clinical Decision Rule for Streptococcal Pharyngitis in Children. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 250-255.	2.0	17
174	Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0268720.	3.4	17
175	Updated recommendations for the management of upper respiratory tract infections in South Africa. <i>South African Medical Journal</i> , 2015, 105, 345.	0.8	16
176	Prolonged tuberculosis-associated immune reconstitution inflammatory syndrome: characteristics and risk factors. <i>BMC Infectious Diseases</i> , 2016, 16, 518.	3.0	16
177	Random lopinavir concentrations predict resistance on lopinavir-based antiretroviral therapy. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 158-162.	3.3	16
178	Quantitative and Functional Differences between Peripheral Blood Myeloid Dendritic Cells from Patients with Pleural and Parenchymal Lung Tuberculosis. <i>Vaccine Journal</i> , 2006, 13, 1299-1306.	3.3	15
179	Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases. <i>HIV Clinical Trials</i> , 2011, 12, 277-285.	2.0	15
180	Etiology of Pulmonary Infections in Human Immunodeficiency Virus-infected Inpatients Using Sputum Multiplex Real-time Polymerase Chain Reaction. <i>Clinical Infectious Diseases</i> , 2020, 70, 1147-1152.	5.7	15

#	ARTICLE	IF	CITATIONS
181	Guidelines for antiretroviral therapy in adults. Southern African Journal of HIV Medicine, 2012, 13, .	0.9	15
182	Pharmacokinetics of bedaquiline in cerebrospinal fluid (CSF) in patients with pulmonary tuberculosis (TB). Journal of Antimicrobial Chemotherapy, 2022, 77, 1720-1724.	3.2	15
183	A model to rule out smear-negative tuberculosis among symptomatic HIV patients using C-reactive protein. International Journal of Tuberculosis and Lung Disease, 2012, 16, 1247-1251.	1.2	14
184	Abdominal Ultrasound for the Diagnosis of Tuberculosis Among Human Immunodeficiency Virus-Positive Inpatients With World Health Organization Danger Signs. Open Forum Infectious Diseases, 2019, 6, ofz094.	0.9	14
185	Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites. Journal of Antimicrobial Chemotherapy, 2019, 74, 699-709.	3.2	14
186	Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.4	14
187	Southern African HIV Clinicians Society adult antiretroviral therapy guidelines: Update on when to initiate antiretroviral therapy. Southern African Journal of HIV Medicine, 2015, 16, 428.	0.9	14
188	Advances in adult pulmonary tuberculosis. Current Opinion in Pulmonary Medicine, 2002, 8, 173-177.	2.7	13
189	Early severe morbidity and resource utilization in South African adults on antiretroviral therapy. BMC Infectious Diseases, 2009, 9, 205.	3.0	13
190	The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals [Short communication]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 333-335.	1.2	13
191	Linezolid for Treating Tuberculosis: A Delicate Balancing Act. EBioMedicine, 2015, 2, 1568-1569.	6.0	13
192	Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive adults. The Cochrane Library, 0, , .	2.8	13
193	Point-of-Care Ultrasound Predictors for the Diagnosis of Tuberculosis in HIV-Positive Patients Presenting to an Emergency Center. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 415-423.	2.2	13
194	A Clinical Prediction Score Including Trial of Antibiotics and C-Reactive Protein to Improve the Diagnosis of Tuberculosis in Ambulatory People With HIV. Open Forum Infectious Diseases, 2020, 7, ofz543.	0.9	13
195	Guideline on the management of occupational and non-occupational exposure to the human immunodeficiency virus and recommendations for post-exposure prophylaxis: 2015 Update. Southern African Journal of HIV Medicine, 2015, 16, 399.	0.9	13
196	Plasma Lopinavir Concentrations Predict Virological Failure in a Cohort of South African Children Initiating a Protease-Inhibitor-Based Regimen. Antiviral Therapy, 2014, 19, 399-406.	1.0	12
197	Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV. Journal of Antimicrobial Chemotherapy, 2020, 75, 1019-1025.	3.2	12
198	Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0239920.	3.4	12

#	ARTICLE	IF	CITATIONS
199	Xpert Ultra testing of blood in severe HIV-associated tuberculosis to detect and measure Mycobacterium tuberculosis blood stream infection: a diagnostic and disease biomarker cohort study. <i>Lancet Microbe</i> , The, 2022, 3, e521-e532.	6.7	12
200	Course and complications of varicella zoster ophthalmicus in a high HIV seroprevalence population (Cape Town, South Africa). <i>Eye</i> , 2009, 23, 376-381.	2.3	11
201	Prolonged deferral of antiretroviral therapy in the SAPIT trial: Did we need a clinical trial to tell us that this would increase mortality?. <i>South African Medical Journal</i> , 2010, 100, 566.	0.8	11
202	Prognostic indicators in the World Health Organization's algorithm for seriously ill HIV-infected inpatients with suspected tuberculosis. <i>AIDS Research and Therapy</i> , 2018, 15, 5.	1.8	11
203	Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial. <i>Wellcome Open Research</i> , 2021, 6, 1.	1.9	11
204	Undisclosed HIV status and antiretroviral therapy use among South African blood donors. <i>Transfusion</i> , 2021, 61, 2392-2400.	1.8	11
205	Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0138121.	3.4	11
206	Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial). <i>JMIR Research Protocols</i> , 2016, 5, e173.	1.0	11
207	Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy. <i>Southern African Journal of HIV Medicine</i> , 2020, 21, 1062.	0.9	11
208	A treatment recommender clinical decision support system for personalized medicine: method development and proof-of-concept for drug resistant tuberculosis. <i>BMC Medical Informatics and Decision Making</i> , 2022, 22, 56.	3.1	11
209	A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus-Associated Tuberculous Meningitis: The LASER-TBM Trial. <i>Clinical Infectious Diseases</i> , 2023, 76, 1412-1422.	5.7	11
210	Acute interstitial nephritis caused by lopinavir/ritonavir in a surgeon receiving antiretroviral postexposure prophylaxis. <i>Aids</i> , 2015, 29, 503-504.	2.2	10
211	Changes in Body Fat Distribution on Dual-Energy X-Ray Absorptiometry in Black South Africans Starting First-Line Antiretroviral Therapy. <i>AIDS Patient Care and STDs</i> , 2016, 30, 455-462.	2.7	10
212	A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 325-329.	2.2	10
213	Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus-1. <i>Clinical Infectious Diseases</i> , 2019, 69, 295-305.	5.7	10
214	Risk of Immune Reconstitution Inflammatory Syndrome With Integrase Inhibitors Versus Other Classes of Antiretrovirals: A Systematic Review and Meta-analysis of Randomized Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 232-239.	2.2	10
215	Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa. <i>AIDS Research and Therapy</i> , 2016, 13, 40.	1.8	9
216	Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. <i>Aids</i> , 2019, 33, 525-536.	2.2	9

#	ARTICLE	IF	CITATIONS
217	A Novel Markov Model Projecting Costs and Outcomes of Providing Antiretroviral Therapy to Public Patients in Private Practices versus Public Clinics in South Africa. <i>PLoS ONE</i> , 2013, 8, e53570.	2.5	9
218	Development of a clinical prediction rule to diagnose <i>Pneumocystis jirovecii</i> pneumonia in the World Health Organization's algorithm for seriously ill HIV-infected patients. <i>Southern African Journal of HIV Medicine</i> , 2018, 19, 851.	0.9	9
219	Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa. <i>Journal of Infectious Diseases</i> , 2022, 226, 147-156.	3.9	9
220	Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.4	9
221	Tuberculosis in the tropics. <i>Clinics in Chest Medicine</i> , 2002, 23, 341-350.	2.2	8
222	Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial. <i>AIDS Research and Therapy</i> , 2017, 14, 6.	1.8	8
223	Brief Report: Real-World Performance and Interobserver Agreement of Urine Lipoarabinomannan in Diagnosing HIV-Associated Tuberculosis in an Emergency Center. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, e10-e14.	2.2	8
224	Diagnosing lymphoma in the shadow of an epidemic: lessons learned from the diagnostic challenges posed by the dual tuberculosis and HIV epidemics. <i>Leukemia and Lymphoma</i> , 2020, 61, 3417-3421.	1.4	8
225	Diagnostic accuracy of WHO screening criteria to guide lateral-flow lipoarabinomannan testing among HIV-positive inpatients: A systematic review and individual participant data meta-analysis. <i>Journal of Infection</i> , 2022, 85, 40-48.	3.4	8
226	CD4 T-cell responses to combination antiretroviral therapy. <i>Lancet, The</i> , 2007, 370, 366-368.	12.1	7
227	The development of simple anthropometric measures to diagnose antiretroviral therapy-associated lipodystrophy in resource limited settings. <i>AIDS Research and Therapy</i> , 2014, 11, 26.	1.8	7
228	Adverse Drug Reactions Reported to a National HIV & Tuberculosis Health Care Worker Hotline in South Africa: Description and Prospective Follow-Up of Reports. <i>Drug Safety</i> , 2016, 39, 159-169.	3.2	7
229	Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis. <i>International Journal of Audiology</i> , 2020, 59, 219-223.	2.1	7
230	Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?. <i>European Respiratory Journal</i> , 2020, 56, 2001369.	7.5	7
231	Diagnostic Accuracy of the INSHI Consensus Case Definition for the Diagnosis of Paradoxical Tuberculosis-IRIS. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 587-592.	2.2	7
232	First-line antiretroviral drug discontinuations in children. <i>PLoS ONE</i> , 2017, 12, e0169762.	2.5	7
233	Correlation of hair and plasma efavirenz concentrations in HIV-positive South Africans. <i>Southern African Journal of HIV Medicine</i> , 2019, 20, 881.	0.9	7
234	Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings. <i>BMC Health Services Research</i> , 2010, 10, S3.	2.2	6

#	ARTICLE	IF	CITATIONS
235	Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study. <i>AIDS Research and Therapy</i> , 2010, 7, 23.	1.8	6
236	Resistance matters in EARNEST. <i>Lancet HIV</i> , 2017, 4, e323-e324.	4.6	6
237	Emtricitabine-associated red cell aplasia. <i>Aids</i> , 2019, 33, 1095-1096.	2.2	6
238	Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 1002-1009.	2.2	6
239	Is HIV/AIDS a primary-care disease? Appropriate levels of outpatient care for patients with HIV/AIDS. <i>Aids</i> , 1995, 9, 619-624.	2.2	5
240	Anthropometric definitions for antiretroviral-associated lipodystrophy derived from a longitudinal South African cohort with serial dual-energy X-ray absorptiometry measurements. <i>International Journal of STD and AIDS</i> , 2018, 29, 1194-1203.	1.2	5
241	AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial. <i>Wellcome Open Research</i> , 0, 6, 33.	1.9	5
242	Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2023, 76, 1832-1840.	5.7	5
243	Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study. <i>AIDS Research and Therapy</i> , 2012, 9, 32.	1.8	4
244	The role of the Infectious Diseases unit at Groote Schuur Hospital in addressing South Africa's greatest burden of disease. <i>South African Medical Journal</i> , 2012, 102, 528.	0.8	4
245	Clinical pharmacology becomes a specialty in South Africa. <i>South African Medical Journal</i> , 2013, 103, 150.	0.8	4
246	The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 1194-1196.	1.2	4
247	Clinician compliance with laboratory monitoring and prescribing guidelines in HIV-1-infected patients receiving tenofovir. <i>South African Medical Journal</i> , 2016, 106, 369.	0.8	4
248	Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, e378-e383.	2.0	4
249	Diagnostic Outcomes After Chest Radiograph Interpretation in Patients With Suspected Tuberculosis and Negative Sputum Smears in a High-Burden Human Immunodeficiency Virus and Tuberculosis Setting. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx123.	0.9	4
250	Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0027821.	3.4	4
251	Effect of dihydroartemisinin/piperaquine for malaria intermittent preventive treatment on dolutegravir exposure in pregnant women living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1733-1737.	3.2	4
252	Diagnosis and treatment of opioid-related disorders in a South African private sector medical insurance scheme: A cohort study. <i>International Journal of Drug Policy</i> , 2022, 109, 103853.	3.5	4

#	ARTICLE	IF	CITATIONS
253	Weight gain on dolutegravir: Association is not the same as causation. Southern African Journal of HIV Medicine, 2023, 24, .	0.9	4
254	Dosing of raltegravir when given with rifampicin. Lancet Infectious Diseases, The, 2014, 14, 442-443.	8.9	3
255	Lower-dose efavirenz: what is needed before implementation?. Lancet Infectious Diseases, The, 2015, 15, 749-751.	8.9	3
256	Factors associated with loss to follow-up after occupational HIV exposure in Cape Town, South Africa: a retrospective cohort study. AIDS Research and Therapy, 2017, 14, 23.	1.8	3
257	Erratum to South African guideline for the management of community-acquired pneumonia in adults. Journal of Thoracic Disease, 2018, 10, E673-E675.	1.4	3
258	Routine data underestimates the incidence of first-line antiretroviral drug discontinuations due to adverse drug reactions: Observational study in two South African cohorts. PLoS ONE, 2018, 13, e0203530.	2.5	3
259	Adult medical emergency unit presentations due to adverse drug reactions in a setting of high HIV prevalence. African Journal of Emergency Medicine, 2021, 11, 46-52.	1.2	3
260	Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid. Southern African Journal of HIV Medicine, 2021, 22, 1206.	0.9	3
261	RivalitÃ©s et arrangements coopÃ©ratifs pour lâ€™accÃ©s Ã© lâ€™eau souterraine dans la plaine de Berrechid au Maroc. Cahiers Agricultures, 2019, 28, 4.	1.1	3
262	Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2022, 226, 1616-1625.	3.9	3
263	Rechallenge after anti-tuberculosis drug-induced liver injury in a high HIV prevalence cohort. Southern African Journal of HIV Medicine, 2022, 23, .	0.9	3
264	Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment. Open Forum Infectious Diseases, 2022, 9, .	0.9	3
265	Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population. Journal of Antimicrobial Chemotherapy, 0, , .	3.2	3
266	Dolutegravir for second-line treatment: Programmatic implications of new evidence. Southern African Journal of HIV Medicine, 2022, 23, .	0.9	3
267	Analysis of serum microRNAâ€122 in a randomized controlled trial of Nâ€acetylcysteine for treatment of antituberculosis drugâ€induced liver injury. British Journal of Clinical Pharmacology, 2023, 89, 1844-1851.	2.3	3
268	Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12, 821-830.	2.5	3
269	Clinical aspects of tuberculosis in HIV-infected adults. , 2009, , 524-531.		2
270	Global HIV/AIDS Clinical and Translational Pharmacology. AIDS Research and Treatment, 2012, 2012, 1-3.	0.7	2



#	ARTICLE	IF	CITATIONS
271	Should tuberculin skin testing be a prerequisite to prolonged IPT for HIV-infected adults? [Perspectives]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2012, 16, 857-859.	1.2	2
272	Diagnosis and treatment of pulmonary tuberculosis in patients with HIV. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 267-268.	8.9	2
273	Correlation of Linezolid Hair Concentrations with Plasma Exposure in Patients with Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.4	2
274	Simultaneous Determination of Carvedilol, Enalaprilat, and Perindoprilat in Human Plasma Using LC-MS/MS and Its Application to a Pharmacokinetic Pilot Study. <i>Chromatographia</i> , 2022, 85, 455-468.	1.3	2
275	A multi-parameter diagnostic clinical decision tree for the rapid diagnosis of tuberculosis in HIV-positive patients presenting to an emergency centre. <i>Wellcome Open Research</i> , 0, 5, 72.	1.9	2
276	Determining antenatal medicine exposures in South African women: a comparison of three methods of ascertainment. <i>BMC Pregnancy and Childbirth</i> , 2022, 22, .	2.4	2
277	Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	3.4	2
278	Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin. <i>Clinical Infectious Diseases</i> , 2024, 78, 1246-1255.	5.7	2
279	Unrecognised <i>Mycobacterium tuberculosis</i> . <i>Lancet</i> , The, 2000, 355, 141.	12.1	1
280	Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.4	1
281	A multi-parameter diagnostic clinical decision tree for the rapid diagnosis of tuberculosis in HIV-positive patients presenting to an emergency centre. <i>Wellcome Open Research</i> , 0, 5, 72.	1.9	1
282	“Covering the tail” after stopping efavirenz-based antiretroviral therapy. <i>Southern African Journal of HIV Medicine</i> , 2020, 21, 1036.	0.9	1
283	Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0174921.	3.4	1
284	The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0013622.	3.4	1
285	Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	3.4	1
286	Cerebrospinal Fluid and Tuberculosis Meningitis. <i>Clinical Infectious Diseases</i> , 0, , .	5.7	1
287	Validation of a quantitative liquid chromatography tandem mass spectrometry assay for linezolid in cerebrospinal fluid and its application to patients with HIV-associated TB-meningitis. <i>Heliyon</i> , 2023, 9, e21962.	3.3	1
288	Response to “CD4 Cell Count Natural History and Informative Censoring in Sub-Saharan Africa”. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 491.	2.2	0

#	ARTICLE	IF	CITATIONS
289	Deteriorating tuberculosis in a HIV-infected man despite treatmentImmune reconstitution, resistance, or drug malabsorption?. , 2009, , 852-853.		0
290	Prevention of opportunistic infections in adults. , 0, , 479-488.		0
291	ART and tuberculosis: the final nail in nevirapine's coffin?. Lancet Infectious Diseases, The, 2013, 13, 278-279.	8.9	0
292	In reply to â€ˆSerum C-reactive protein measurement for ruling out HIV-associated tuberculosisâ€™™ [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 284-284.	1.2	0
293	Managing Human Immunodeficiency Virusâ€™ associated Tuberculosis in the Dolutegravir Era. Clinical Infectious Diseases, 2020, 70, 557-558.	5.7	0
294	Pharmacogenetics of Efavirenz: Adherence and Virologic Outcomes. Annals of Internal Medicine, 2007, 147, 817.	10.2	0
295	Co-treatment of Tuberculosis and HIV: Pharmacologic Considerations. , 2019, , 239-267.		0
296	A comparison of the population pharmacokinetics of rifampicin, isoniazid and pyrazinamide between hospitalized and non-hospitalized tuberculosis patients with or without HIV. Wellcome Open Research, 0, 7, 72.	1.9	0
297	Routine antiretroviral pharmacy refill information can predict failure postpartum in previously suppressed South African women living with HIV. Open Forum Infectious Diseases, 0, ,	0.9	0
298	Introduction to the special issue on integration of human factors and ergonomics. EURO Journal on Transportation and Logistics, 2022, 11, 100098.	2.2	0
299	Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis. Wellcome Open Research, 0, 7, 72.	1.9	0
300	Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis. Wellcome Open Research, 0, 7, 72.	1.9	0
301	Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 0, , OF1-OF8.	1.9	0